Abstract
The Met gene, which encodes a receptor tyrosine kinase, is crucial in cancer cell proliferation and survival. Fluorescence in situ hybridization (FISH) is vital for assessing MET-gene amplification in non-small cell lung cancer (NSCLC). Manual FISH assays are time-consuming and results are critical for treatment decision; automation could reduce turnaraound time. This study evaluates the potentional benefits of the automated FISH-system, Oncore Pro X (biocare Medical USA), by assessing factors including results, turnaround time, and cost.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | International Journal of Biomedical Laboratory Science |
| Vol/bind | 14 |
| Udgave nummer | 1 |
| Sider (fra-til) | 24-38 |
| ISSN | 2308-7706 |
| Status | Udgivet - 2025 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Raising the Bar in the Diagnosis of Non-Small Cell Lung Cancer (NSCLC): The Impact of Automated FISH Technology'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver